UY32128A - Combinaciones sinérgicas de un inhibidor macrocíclico del vhc y un nucleósido - Google Patents

Combinaciones sinérgicas de un inhibidor macrocíclico del vhc y un nucleósido

Info

Publication number
UY32128A
UY32128A UY0001032128A UY32128A UY32128A UY 32128 A UY32128 A UY 32128A UY 0001032128 A UY0001032128 A UY 0001032128A UY 32128 A UY32128 A UY 32128A UY 32128 A UY32128 A UY 32128A
Authority
UY
Uruguay
Prior art keywords
nucleoside
hcv inhibitor
macrocyclic hcv
synergic combinations
synergic
Prior art date
Application number
UY0001032128A
Other languages
English (en)
Inventor
Tse-I Lin
Lenz Oliver
Original Assignee
Ortho Mcneil Janssen Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Janssen Pharm filed Critical Ortho Mcneil Janssen Pharm
Publication of UY32128A publication Critical patent/UY32128A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se relaciona con una combinación sinérgica del compuesto de la fórmula I: o una de sus sales farmacéuticamente aceptables, y el compuesto de la fórmula II: o una de sus sales farmacéuticamente aceptables.
UY0001032128A 2008-09-18 2009-09-18 Combinaciones sinérgicas de un inhibidor macrocíclico del vhc y un nucleósido UY32128A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08164612 2008-09-18

Publications (1)

Publication Number Publication Date
UY32128A true UY32128A (es) 2010-03-26

Family

ID=40076811

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032128A UY32128A (es) 2008-09-18 2009-09-18 Combinaciones sinérgicas de un inhibidor macrocíclico del vhc y un nucleósido

Country Status (20)

Country Link
US (1) US20110171174A1 (es)
EP (1) EP2341907A1 (es)
JP (1) JP2012502956A (es)
KR (1) KR20110054056A (es)
CN (1) CN102164602A (es)
AP (1) AP2011005608A0 (es)
AR (1) AR073603A1 (es)
AU (1) AU2009294622A1 (es)
BR (1) BRPI0919404A2 (es)
CA (1) CA2737835A1 (es)
CO (1) CO6351740A2 (es)
EA (1) EA201170456A1 (es)
EC (1) ECSP11010902A (es)
IL (1) IL211599A0 (es)
MX (1) MX2011002896A (es)
PA (1) PA8842901A1 (es)
TW (1) TW201023858A (es)
UY (1) UY32128A (es)
WO (1) WO2010031829A1 (es)
ZA (1) ZA201102047B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
BRPI0918653A2 (pt) 2008-09-17 2015-12-01 Boehringer Ingelheim Int combinação de inibidor de ns3 protese de hcv com interferon e ribavirina.
WO2011053617A1 (en) 2009-10-30 2011-05-05 Boehringer Ingelheim International Gmbh Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
KR20130057990A (ko) * 2010-04-13 2013-06-03 얀센 파마슈티칼즈, 인코포레이티드 마크로사이클릭 ｈｃｖ 저해제, 비뉴클레오시드 및 뉴클레오시드의 배합물
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
ES2701020T3 (es) 2010-09-22 2019-02-20 Alios Biopharma Inc Nucleósidos azido y análogos nucleotídicos
BR112013007423A2 (pt) * 2010-09-30 2016-07-12 Boehringer Ingelheim Int terapia combinada no que diz respeito ao tratamento da infecção por hcv
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8466159B2 (en) * 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) * 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
KR20150074051A (ko) 2012-10-19 2015-07-01 브리스톨-마이어스 스큅 컴퍼니 C형 간염 바이러스 억제제
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RS61767B1 (sr) * 2012-12-21 2021-05-31 Janssen Biopharma Inc 4'-fluor-nukleozidi, 4'-fluor-nukleotidi i njihovi analozi za lečenje hcv
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
WO2018017989A1 (en) * 2016-07-22 2018-01-25 Janssen Pharmaceuticals, Inc. Combination therapy regimen for treatment of selected hcv genotypes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
CL2007000361A1 (es) * 2006-02-09 2008-01-25 Wyeth Corp Combinacion que comprende un inhibidor de la arn polimerasa del virus de la hepatitis c (vhc) y un inhibidor de la proteasa del vhc; composicion farmaceutica que la comprende; y uso de la combinacion para tratar trastornos asociados con vhc.
US20070274951A1 (en) * 2006-02-09 2007-11-29 Xiao Tong Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
AP2009004812A0 (en) * 2006-10-10 2009-04-30 Medivir Ab HCV nucleoside inhibitor

Also Published As

Publication number Publication date
ECSP11010902A (es) 2011-06-30
PA8842901A1 (es) 2010-04-21
CN102164602A (zh) 2011-08-24
WO2010031829A1 (en) 2010-03-25
AP2011005608A0 (en) 2011-04-30
AR073603A1 (es) 2010-11-17
CA2737835A1 (en) 2010-03-25
CO6351740A2 (es) 2011-12-20
TW201023858A (en) 2010-07-01
IL211599A0 (en) 2011-05-31
BRPI0919404A2 (pt) 2015-12-15
EA201170456A1 (ru) 2011-08-30
KR20110054056A (ko) 2011-05-24
US20110171174A1 (en) 2011-07-14
ZA201102047B (en) 2012-08-29
MX2011002896A (es) 2011-08-15
JP2012502956A (ja) 2012-02-02
AU2009294622A1 (en) 2010-03-25
EP2341907A1 (en) 2011-07-13

Similar Documents

Publication Publication Date Title
ECSP11010902A (es) Combinaciones sinérgicas de un inhibidor macrocíclico del vhc y un nucleósido
UY32730A (es) Inhibidores de cyp17
CO6300942A2 (es) Piridinas y pirazinas como inhibidores de p13k
PA8850801A1 (es) Compuestos útiles para inhibir chk1
CR20150183A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
UA106748C2 (uk) Похідні проліну як інгібітори катепсину
NI201100049A (es) Compuestos orgánicos.
CR20120397A (es) Inhibidores del virus de la hepatitis c
ATE519764T1 (de) Spiroindolinon-derivate
RS54386B1 (en) ANTIVIRAL UNITS
HN2011000209A (es) Compuestos macrociclicos de quinoxalina como inhibidores de la proteasa ns3 de vhc
CU20090017A7 (es) Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (iap)
CL2011002857A1 (es) Compuestos derivados de fenil o heteroaril piridina, inhibidores de sintasa de aldosterona; composicion farmaceutica que comprende un compuesto; combinacion farmaceutica que comprende un compuesto; y uso de los compuestos en el tratamiento de enfermedades cardiovasculares.
CR9694A (es) Inhibidores de la transcriptasa reversa de vih
ES2572001T3 (es) Derivado de bisfurano antivírico como inhibidor de la proteasa del VIH e intermedios del mismo
CR20110219A (es) Ácidos naftilacéticos
AR093738A1 (es) Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos
PA8846401A1 (es) Sinergismo antibiótico
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
CL2011000292A1 (es) Compuestos derivados de enfumafungina y sus sales farmaceuticamente aceptables, como inhibidores de (1,3)-beta-d-glucano sintasa; composicion farmaceutica; y uso para tratar una infeccion fungica.
BRPI1012963A2 (pt) compostos inibidores da 11-beta-hidroxisteróide dehidrogenase tipo 1.
EA201001517A1 (ru) Замещенные пиперидины в качестве терапевтических соединений
ES2530436T3 (es) Combinación
ATE481395T1 (de) Cyclohexylderivate